These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 15581984)

  • 1. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.
    Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D
    Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
    Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
    Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
    Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
    Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
    Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
    J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of early ovarian cancer: germ cell and sex cord-stromal tumors.
    Gershenson DM
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S62-72. PubMed ID: 7530680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors.
    Stern JW; Bunin N
    Med Pediatr Oncol; 2002 Sep; 39(3):163-7. PubMed ID: 12210444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
    Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
    Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
    Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
    Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of advanced ovarian juvenile granulosa cell tumors.
    Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
    Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
    Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
    J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant retroperitoneal and abdominal germ cell tumors: an intergroup study.
    Billmire D; Vinocur C; Rescorla F; Colombani P; Cushing B; Hawkins E; Davis M; London WB; Lauer S; Giller R;
    J Pediatr Surg; 2003 Mar; 38(3):315-8; discussion 315-8. PubMed ID: 12632341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
    Homesley HD; Bundy BN; Hurteau JA; Roth LM
    Gynecol Oncol; 1999 Feb; 72(2):131-7. PubMed ID: 10021290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
    Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
    J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.